EcoDrugPlus

Tgf-Beta Receptor Type-1-Like

Ensembl ID : ENSSFOG00015027494
Gene Symbol: LOC108935415
3 Cross references
206 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSSFOG00015013083
Gene Symbol: WEE1
3 Cross references
148 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSSFOG00015001214
Gene Symbol: YES1
3 Cross references
265 Possible Orthologues:

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSSFOG00015010678
Gene Symbol: ACHE
3 Cross references
233 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSSFOG00015023798
Gene Symbol: ACVR2B
3 Cross references
195 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSSFOG00015023604
Gene Symbol: ADORA1
3 Cross references
248 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSSFOG00015024329
Gene Symbol: ADORA2A
3 Cross references
258 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSSFOG00015024949
Gene Symbol: ADORA2A
3 Cross references
258 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSSFOG00015015124
Gene Symbol: ADORA2B
3 Cross references
200 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSSFOG00015000358
Gene Symbol: ADA
3 Cross references
216 Possible Orthologues:

Adenosine Receptor A1-Like

Ensembl ID : ENSSFOG00015022655
Gene Symbol: LOC108931201
3 Cross references
152 Possible Orthologues:

Adenosine Receptor A3-Like

Ensembl ID : ENSSFOG00015022960
Gene Symbol: LOC108939165
2 Cross references
179 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).